To answer these queries, we took into account patient clinical-pathological factors, such as expression of progesterone receptors (PR) and ERα in cancer tissue, disease stage, lymph node metastasis, histological tumor type, presence or absence of menstrual cycle, applied neoadjuvant chemotherapy, age. This evidence concerns the gene PGR and neoplasm.